Valuation : Annexon, Inc.

Market Cap 935M 806M 760M 692M 1.29B 88.29B 1.3B 8.99B 3.49B 45.14B 3.51B 3.43B 148B P/E 2026 *
-4.75x
P/E 2027 * -5.04x
Enterprise Value 844M 728M 686M 625M 1.17B 79.74B 1.18B 8.12B 3.15B 40.77B 3.17B 3.1B 134B EV / Sales 2026 *
-
EV / Sales 2027 * 21.9x
Free-Float
94.44%
Yield 2026 *
-
Yield 2027 * -
1 day-0.91%
1 week-7.05%
Current month-1.21%
1 month-7.05%
3 months-9.46%
6 months-10.13%
Current year-2.79%
1 week 4.78
Extreme 4.78
5.2
1 month 4.78
Extreme 4.78
5.7
Current year 4.46
Extreme 4.46
7.18
1 year 2.04
Extreme 2.04
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.61
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 30/11/2014
Director of Finance/CFO 53 31/05/2019
Chief Tech/Sci/R&D Officer 68 26/07/2023
Director TitleAgeSince
Director/Board Member 58 30/11/2014
Director/Board Member 67 04/02/2021
Director/Board Member 56 31/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Director

175,000 0.0923%
28/05/26
Alerce Investment Management LP
BuyCompany 613,497 0.3775%
11/05/26 Buy

Director

8,000 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-0.91%-7.05%+138.05%+82.09% 935M
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.15%+0.40%+49.25%+91.83% 65.29B
-0.28%+3.69%-12.29%+377.32% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-1.21%-8.03%+2.03%-16.02% 26.08B
+1.01%+1.38%+26.48%-17.50% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.22%+7.15%+60.20%+165.87% 14.5B
Average +0.92%-2.51%+56.97%+173.19% 28.13B
Weighted average by Cap. +1.03%-2.12%+42.93%+141.94%

Financials

2026 *2027 *
Net sales - 38.92M 33.57M 31.63M 28.82M 53.86M 3.68B 54.27M 374M 145M 1.88B 146M 143M 6.17B
Net income -212M -183M -172M -157M -293M -19.99B -295M -2.04B -790M -10.22B -795M -777M -33.58B -209M -181M -170M -155M -290M -19.78B -292M -2.01B -782M -10.11B -786M -769M -33.21B
Net Debt -90.55M -78.12M -73.59M -67.05M -125M -8.55B -126M -871M -338M -4.37B -340M -333M -14.37B -80.71M -69.63M -65.59M -59.76M -112M -7.62B -113M -777M -301M -3.9B -303M -296M -12.8B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
92
Date Price Change Volume
03/09/26 US$4.895 -0.71% 274,669
02/09/26 US$4.930 +0.82% 1,842,212
01/09/26 US$4.890 -1.01% 1,472,605
31/08/26 US$4.940 -0.60% 2,436,868
28/08/26 US$4.970 -5.33% 1,618,594
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.930USD
Average target price
15.29USD
Spread / Average Target
+210.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock